HOPE: Clinical, Pathology, and Imaging Project for Brain Tumors
Official title: Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
Run by Beijing Tiantan Hospital · NCT05859659 · Data updated 2026-11-12
This project collects clinical records, MRI scans, and pathology data from people with glioma and other primary brain tumors to build large databases for improving diagnosis and care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 70000 (estimated) |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | January 1, 2022 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | March 9, 2026 |
| Trial ID | NCT05859659 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with a pathologically confirmed glioma who can undergo MRI with sufficient image quality, provide informed consent, and complete clinical follow-up.
✕Probably not a fit
People without a pathological glioma diagnosis, those with prior surgery/biopsy or prior radiation or chemotherapy before enrollment, those with other neurological diseases, or those unable to tolerate MRI or complete follow-up are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
HOPE will create a multivariate retrospective CNS tumor database of over 50,000 cases (including about 10,000 glioma) that integrates clinical information, preoperative MRI, and molecular pathology. A parallel prospective glioma cohort of roughly 3,000 cases will capture advanced MRI sequences and standardized postoperative follow-up. The project is observational and non-interventional, requiring informed consent and high-quality imaging, with exclusions for prior treatment or other neurological diseases. Data will be collected at Beijing Tiantan Hospital and standardized to support radiogenomic analyses, prognostic modeling, and future research use.
Why it matters
Potential benefit: If successful, the database could enable better imaging-based diagnosis, more accurate prognosis models, and more personalized treatment planning for people with glioma.
How similar studies have gone: Large public imaging-pathology initiatives (for example TCGA and BraTS) have demonstrated that integrated databases can advance glioma radiogenomics and prognostic research, so this approach builds on prior successes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) a clear diagnosis of glioma based on pathological results; * (2) The MRI sequence is complete and there are no obvious artifacts in the image; * (3) The patient signs an informed consent form Exclusion Criteria: * (1) Suffering from other neurological diseases; * (2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or chemotherapy; * (3) Unable to complete clinical scoring and related laboratory tests, unable to complete follow-up; * (4) Unable to tolerate MRI examination; Poor image quality, such as motion artifacts.
Where it's running
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Yaou Liu, Doctor — Beijing Tiantan Hospital
- Study coordinator: Yaou Liu, Doctor
- Email: yaouliu80@163.com
- Phone: +86 1059975396
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
Pharmacoscopy-guided treatment for refractory brain tumors
This trial tests whether personalized drug testing on a patient’s tumor cells can guide treatment choices for adults with hard-to-treat brain cancers like glioblastoma.
-
Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer
This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.
-
Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma
This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.
-
Using MRI to Differentiate Between Brain Tumors and Radiation Effects
This study is testing a new MRI technique to see if it can help tell the difference between brain tumors and radiation damage in people who have had radiation therapy.
-
Detecting microplastics in patients undergoing neurosurgery
This study is trying to see if tiny pieces of plastic are found in the blood, brain fluid, and brain tissue of patients who are having brain surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.